{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T06:48:15Z","timestamp":1790318895013,"version":"4.1.0"},"reference-count":94,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1631,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1111\/j.1467-789x.2011.00860.x","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T07:16:44Z","timestamp":1300173404000},"page":"593-601","source":"Crossref","is-referenced-by-count":53,"title":["Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential"],"prefix":"10.1111","volume":"12","author":[{"given":"S. S.","family":"Torekov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. J.","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/ijo.2008.102","article-title":"Global burden of obesity in 2005 and projections to 2030","volume":"32","author":"Kelly","year":"2008","journal-title":"Int J Obes (Lond)"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB2|cit2","unstructured":"Akram DS Astrup AV Atinmo T Boissin JL Bray GA Carroll KK Chitson P Chunming C Dietz WH Hill JO Jequier E Komodiki C Matsuzawa Y Mollentze WF Moosa K Noor MI Reddy KS Seidell J Tanphaichitr V Uauy R Zimmet P Obesity: preventing and managing the global epidemic World Health Organization 2000"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.soard.2007.08.004","article-title":"Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding","volume":"3","author":"Korner","year":"2007","journal-title":"Surg Obes Relat Dis"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/joe.0.1380159","article-title":"Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns","volume":"138","author":"Elliott","year":"1993","journal-title":"J Endocrinol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.2174\/1381612033454775","article-title":"Central pre-proglucagon derived peptides: opportunities for treatment of obesity","volume":"9","author":"Larsen","year":"2003","journal-title":"Curr Pharm Des"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/sj.ijo.0800818","article-title":"Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men","volume":"23","author":"N\u00e4slund","year":"1999","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1172\/JCI990","article-title":"Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans","volume":"101","author":"Flint","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1210\/en.2008-1045","article-title":"Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety","volume":"150","author":"Williams","year":"2009","journal-title":"Endocrinology"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/379069a0","article-title":"A role for glucagon-like peptide-1 in the central regulation of feeding","volume":"379","author":"Turton","year":"1996","journal-title":"Nature"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cne.902710405","article-title":"Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study","volume":"271","author":"Jin","year":"1988","journal-title":"J Comp Neurol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0306-4522(96)00434-4","article-title":"Distribution of glucagon-like peptide-1 and other preproglucagon-derived peptides in the rat hypothalamus and brainstem","volume":"77","author":"Larsen","year":"1997","journal-title":"Neuroscience"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB12|cit12","first-page":"363","volume-title":"Obesity in Europe 1993","author":"Schick","year":"1994"},{"issue":"4","key":"10.1111\/j.1467-789X.2011.00860.x-BIB13|cit13","first-page":"R848","article-title":"Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats","volume":"271","author":"Tang-Christensen","year":"1996","journal-title":"Am J Physiol"},{"issue":"2","key":"10.1111\/j.1467-789X.2011.00860.x-BIB14|cit14","first-page":"R582","article-title":"Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus","volume":"277","author":"Rinaman","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.regpep.2004.08.026","article-title":"Glucagon-related peptide 1 (GLP-1): hormone and neurotransmitter","volume":"128","author":"Larsen","year":"2005","journal-title":"Regul Pept"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"R470","DOI":"10.1152\/ajpregu.00732.2002","article-title":"Gastric distension induces c-Fos in medullary GLP-1\/2-containing neurons","volume":"285","author":"Vrang","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1111\/j.1460-9568.1995.tb00650.x","article-title":"Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites","volume":"7","author":"G\u00f6ke","year":"1995","journal-title":"Eur J Neurosci"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2337\/diabetes.47.4.530","article-title":"Glucagon-like peptide 1 (7-36) amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment","volume":"47","author":"Tang-Christensen","year":"1998","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"4244","DOI":"10.1210\/en.142.10.4244","article-title":"Oxyntomodulin inhibits food intake in the rat","volume":"142","author":"Dakin","year":"2001","journal-title":"Endocrinology"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/77535","article-title":"The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake [In Process Citation]","volume":"6","author":"Tang-Christensen","year":"2000","journal-title":"Nat Med"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/gut.44.1.81","article-title":"Glucagon-like peptide-1: a potent regulator of food intake in humans","volume":"44","author":"Gutzwiller","year":"1999","journal-title":"Gut"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB22|cit22","first-page":"860","article-title":"Liraglutide: short-lived effect on gastric emptying - long-lasting effects on body-weight","volume":"53","author":"Knudsen","year":"2010","journal-title":"Diabetologia"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/en.2008-1221","article-title":"Intrameal hepatic portal and intraperitoneal infusions of glucagon-like peptide-1 reduce spontaneous meal size in the rat via different mechanisms","volume":"150","author":"Ruttimann","year":"2009","journal-title":"Endocrinology"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"832","DOI":"10.2337\/diabetes.45.6.832","article-title":"Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I","volume":"45","author":"Orskov","year":"1996","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.2337\/db07-1824","article-title":"Arcuate glucagon-like peptide 1 receptors regulate glucose homeostasis but not food intake","volume":"57","author":"Sandoval","year":"2008","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1053\/j.gastro.2008.01.017","article-title":"An albumin-exendin-4 conjugate engages central and peripheral circuits regulating murine energy and glucose homeostasis","volume":"134","author":"Baggio","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1566-0702(02)00182-0","article-title":"Glucagon-like peptide-1 evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons","volume":"102","author":"Kakei","year":"2002","journal-title":"Auton Neurosci"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1365-2982.2009.01317.x","article-title":"Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat","volume":"21","author":"Bucinskaite","year":"2009","journal-title":"Neurogastroenterol Motil"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.2337\/db07-1775","article-title":"Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis","volume":"57","author":"Picha","year":"2008","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.2337\/db06-0730","article-title":"Ghrelin attenuates the inhibitory effects of glucagon-like peptide-1 and peptide YY (3-36) on food intake and gastric emptying in rats","volume":"55","author":"Chelikani","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1172\/JCI275","article-title":"Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus","volume":"101","author":"Jensen","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm1196-1254","article-title":"Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene","volume":"2","author":"Scrocchi","year":"1996","journal-title":"Nat Med"},{"issue":"2","key":"10.1111\/j.1467-789X.2011.00860.x-BIB34|cit34","first-page":"A380","article-title":"Exenatide does not cause pancreatic tumours or malignancies in rats and mice following a 2-year period of exposure","volume":"53","author":"Hiles","year":"2004","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/jc.86.9.4382","article-title":"A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans","volume":"86","author":"Verdich","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB36|cit36","first-page":"529","article-title":"Diurnal profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in human morbid obesity","volume":"7","author":"Holst","year":"1983","journal-title":"Int J Obes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1023\/A:1018806129102","article-title":"Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying","volume":"43","author":"N\u00e4slund","year":"1998","journal-title":"Dig Dis Sci"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/00365527909179871","article-title":"Plasma enteroglucagon after jejunoileal bypass with 3:1 or 1:3 jejunoileal ratio","volume":"14","author":"Holst","year":"1979","journal-title":"Scand J Gastroenterol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/sj.ijo.0801655","article-title":"The role of postprandial releases of insulin and incretin hormones in meal-induced satiety-effect of obesity and weight reduction","volume":"25","author":"Verdich","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2337\/diacare.24.9.1640","article-title":"Impaired incretin response after a mixed meal is associated with insulin resistance in nondiabetic men","volume":"24","author":"Rask","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/gut.38.6.916","article-title":"Attenuated GLP-1 secretion in obesity: cause or consequence?","volume":"38","author":"Ranganath","year":"1996","journal-title":"Gut"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/CS19980308","article-title":"Inhibition of carbohydrate-mediated glucagon-like peptide-1 (7-36) amide secretion by circulating non-esterified fatty acids","volume":"96","author":"Ranganath","year":"1999","journal-title":"Clin Sci (Colch)"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1210\/jc.86.8.3717","article-title":"Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients","volume":"86","author":"Toft-Nielsen","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.2337\/db07-1315","article-title":"Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients","volume":"57","author":"Muscelli","year":"2008","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00125-010-1937-z","article-title":"Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice","volume":"54","author":"Maida","year":"2011","journal-title":"Diabetologia"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1515\/bc.2010.139","article-title":"Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal beta-cells","volume":"391","author":"McKiney","year":"2010","journal-title":"Biol Chem"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB47|cit47","first-page":"572","article-title":"Sitagliptin and metformin increase active GLP-1 by complementary mechanisms in treatment-na\u00efve patients with type 2 diabetes","volume":"1","author":"Migoya","year":"2010","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1210\/jc.2005-0904","article-title":"Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects","volume":"91","author":"Morinigo","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1007\/s00125-005-1933-x","article-title":"Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia","volume":"48","author":"Patti","year":"2005","journal-title":"Diabetologia"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.sla.0000183349.16877.84","article-title":"Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters","volume":"243","author":"Le Roux","year":"2006","journal-title":"Ann Surg"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.2337\/db06-0068","article-title":"Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery","volume":"55","author":"Guidone","year":"2006","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2337\/dc09-1374","article-title":"Postprandial diabetic glucose tolerance is normalized by gastric bypass feeding as opposed to gastric feeding and is associated with exaggerated GLP-1 secretion: a case report","volume":"33","author":"Dirksen","year":"2010","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1111\/j.1467-789X.2011.00860.x-BIB53|cit53","first-page":"R1541","article-title":"Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2","volume":"276","author":"Gutzwiller","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(02)07952-7","article-title":"Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study","volume":"359","author":"Zander","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1055\/s-2002-29087","article-title":"Endoproteolysis by isolated membrane peptidases reveal metabolic stability of glucagon-like peptide-1 analogs, exendins-3 and -4","volume":"110","author":"Thum","year":"2002","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.2337\/diacare.28.5.1083","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea","volume":"28","author":"Kendall","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.2337\/diacare.27.11.2628","article-title":"Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes","volume":"27","author":"Buse","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB60|cit60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079907X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly vs. twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dc06-2375","article-title":"Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes","volume":"30","author":"Kim","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2337\/dc09-1914","article-title":"DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/dmrr.646","article-title":"Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin","volume":"22","author":"Riddle","year":"2006","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB65|cit65","first-page":"8","article-title":"Duration-5: exenatide once weekly resulted in significantly greater improvement in glycemic control with less nausea than exenatide twice daily in patients with type 2 diabetes","volume":"59","author":"Blevin","year":"2010","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1210\/jc.2008-0115","article-title":"Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome","volume":"93","author":"Elkind-Hirsch","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB68|cit68","first-page":"542","article-title":"Maintenance of diet with exenatide lasts - the model study","volume":"59","author":"Smith","year":"2010","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mce.2008.11.018","article-title":"Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue","volume":"297","author":"Russell-Jones","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day vs. exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2337\/dc08-1355","article-title":"Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study","volume":"32","author":"Nauck","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc08-2124","article-title":"Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD)","volume":"32","author":"Zinman","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide vs. glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/oby.2007.204","article-title":"Liraglutide, a once-daily human glucagon-like peptide-1 analog, minimizes food intake in severely obese minipigs","volume":"15","author":"Raun","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.2337\/dc09-2260","article-title":"Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents","volume":"33","author":"Buse","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","article-title":"Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue","volume":"11","author":"Jendle","year":"2009","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB79|cit79","first-page":"381","article-title":"Prediction of type 2 diabetes with the novel metabolic syndrome consensus definition: the importance of waist circumference","volume":"59","author":"Saely","year":"2010","journal-title":"Diabetes"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB80|cit80","first-page":"1894","article-title":"The human Glp-1 analog, liraglutide, improves bmi and waist circumference in patients with type 2 diabetes: meta-analysis of six phase 3 trials","volume":"59","author":"Zinman","year":"2010","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0140-6736(10)60226-7","article-title":"Liraglutide for weight loss in obese people","volume":"375","author":"Thum","year":"2010","journal-title":"Lancet"},{"issue":"2","key":"10.1111\/j.1467-789X.2011.00860.x-BIB83|cit83","first-page":"S51","article-title":"Treatment with Liraglutide, a once-daily human GLP-1 analog, for 52 weeks reduces weight and waist circumference: a randomized placebo-controlled trial","volume":"17","author":"Astrup","year":"2009","journal-title":"Obesity"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB84|cit84","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0140-6736(10)60225-5","article-title":"Liraglutide for weight loss in obese people","volume":"375","author":"Hallberg","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB85|cit85","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1463-1326.2008.00992.x","article-title":"Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects","volume":"11","author":"Bush","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB86|cit86","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB87|cit87","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1210\/en.2009-1459","article-title":"Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency","volume":"151","author":"Sebokova","year":"2010","journal-title":"Endocrinology"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB88|cit88","first-page":"58","article-title":"Once weekly taspoglutide, a human glp-1 analog, is superior to sitagliptin in improving glycemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial","volume":"59","author":"Bergenstal","year":"2010","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB89|cit89","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1037\/0003-066X.62.3.220","article-title":"Medicare's search for effective obesity treatments: diets are not the answer","volume":"62","author":"Mann","year":"2007","journal-title":"Am Psychol"},{"issue":"1","key":"10.1111\/j.1467-789X.2011.00860.x-BIB90|cit90","first-page":"1312","article-title":"Patient willingness-to-pay for liraglutide and glimepiride based on head-to-head clinical trial results","volume":"59","author":"Jendle","year":"2010","journal-title":"Diabetes"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB91|cit91","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB92|cit92","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1550-8528.1999.tb00709.x","article-title":"Pharmaceutical cost savings of treating obesity with weight loss medications","volume":"7","author":"Greenway","year":"1999","journal-title":"Obes Res"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB93|cit93","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jada.2007.05.015","article-title":"Effects of lifestyle intervention on health care costs: improving Control with Activity and Nutrition (ICAN)","volume":"107","author":"Wolf","year":"2007","journal-title":"J Am Diet Assoc"},{"key":"10.1111\/j.1467-789X.2011.00860.x-BIB94|cit94","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2337\/db09-1859","article-title":"PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans","volume":"59","author":"Field","year":"2010","journal-title":"Diabetes"}],"container-title":["Obesity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1467-789X.2011.00860.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1467-789X.2011.00860.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,20]],"date-time":"2021-11-20T09:20:01Z","timestamp":1637400001000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1467-789X.2011.00860.x"}},"subtitle":["Obesity - an indication for GLP-1 treatment?"],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":94,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1467-789x.2011.00860.x","relation":{},"ISSN":["1467-7881"],"issn-type":[{"value":"1467-7881","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,15]]}}}